Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.
Diabetes, obesity & metabolism · Abstract available
All research
COMPOUND RESEARCH
Orforglipron
Follow the papers. Understand the context.
10 papers · 5 trial recordsChecked 18 Sept 2026
This is a non-peptide compound included in the site's existing reference collection.
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06045221 · completed · Results posted
Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.
BMC endocrine disorders · Abstract available
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 · completed · No results posted in this snapshot
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
NCT07793019 · recruiting · No results posted in this snapshot
Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.
American journal of nephrology · Abstract available
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471 · recruiting · No results posted in this snapshot
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884 · recruiting · No results posted in this snapshot
Keeping the weight off: can oral orforglipron maintain all the weight loss following glucagon-like peptide-1 receptor agonist (GLP-1 RA) discontinuation?
Expert review of clinical pharmacology · Citation only
Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.
The lancet. Diabetes & endocrinology · Abstract available
Safety and tolerability of orforglipron in Japanese people with type 2 diabetes.
The lancet. Diabetes & endocrinology · Citation only
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary.
JAMA · Citation only
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
JAMA · Abstract available
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.
Frontiers in pharmacology · Abstract available
Publications match compound names in their titles. Trial matches use intervention names. An association with a compound is not a finding about its effectiveness. How we select records.